Mandate

Vinge advises on division of Creades

January 24, 2013

On the initiative of the majority shareholders, Bioinvestor and Pan Capital, it is proposed that Creades (NASDAQ OMX First North) will be divided into two companies pursuant to a squeeze out procedure whereby 30 per cent of Creades’ net worth will be transferred to a new, unlisted company, Sedarec, which will be distributed to the shareholders in the manner desired by them. Pan Capital will become the majority shareholder in Sedarec which, following completion of the squeeze out procedure, will be liquidated under Pan Capital’s management, whereas Creades, with Bioinvestor as its majority shareholder, will continue its long-term strategy.

Vinge team advising Creades primarily consisted of partner Erik Sjöman and associate Jo-Anna Nordström.

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024